Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Talha Badar; Ehab Atallah; Rory M. Shallis; Aaron D. Goldberg; Anand Patel; Yasmin Abaza; Jan P. Bewersdorf; Antoine N. Saliba; Guilherme Sacchi De Camargo Correia; Guru Murthy; Adam Duvall; Madelyn Burkart; Maximilian Stahl; Yuanhang Liu; Shira Dinner; Neil Palmisiano; Mark R. Litzow; James M. Foran

doi:10.1002/ajh.26546

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

Talha Badar, Ehab Atallah, Rory M. Shallis, Aaron D. Goldberg, Anand Patel, Yasmin Abaza, Jan P. Bewersdorf, Antoine N. Saliba, Guilherme Sacchi De Camargo Correia, Guru Murthy, Adam Duvall, Madelyn Burkart, Maximilian Stahl, Yuanhang Liu, Shira Dinner, Neil Palmisiano, Mark R. Litzow, James M. Foran

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	E232-E235
Journal	American journal of hematology
Volume	97
Issue number	7
DOIs	https://doi.org/10.1002/ajh.26546
State	Published - Jul 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26546

Cite this

Badar, T., Atallah, E., Shallis, R. M., Goldberg, A. D., Patel, A., Abaza, Y., Bewersdorf, J. P., Saliba, A. N., Correia, G. S. D. C., Murthy, G., Duvall, A., Burkart, M., Stahl, M., Liu, Y., Dinner, S., Palmisiano, N., Litzow, M. R., & Foran, J. M. (2022). Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American journal of hematology, 97(7), E232-E235. https://doi.org/10.1002/ajh.26546

Badar, T, Atallah, E, Shallis, RM, Goldberg, AD, Patel, A, Abaza, Y, Bewersdorf, JP, Saliba, AN, Correia, GSDC, Murthy, G, Duvall, A, Burkart, M, Stahl, M, Liu, Y, Dinner, S, Palmisiano, N, Litzow, MR & Foran, JM 2022, 'Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival', American journal of hematology, vol. 97, no. 7, pp. E232-E235. https://doi.org/10.1002/ajh.26546

@article{ca3fab0951ae46228fd51c710ef9a258,

title = "Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival",

author = "Talha Badar and Ehab Atallah and Shallis, {Rory M.} and Goldberg, {Aaron D.} and Anand Patel and Yasmin Abaza and Bewersdorf, {Jan P.} and Saliba, {Antoine N.} and Correia, {Guilherme Sacchi De Camargo} and Guru Murthy and Adam Duvall and Madelyn Burkart and Maximilian Stahl and Yuanhang Liu and Shira Dinner and Neil Palmisiano and Litzow, {Mark R.} and Foran, {James M.}",

note = "Funding Information: Talha Badar received Mayo Clinic Cancer Center support grant (P30 CA015083) and in advisory board for Pfizer; Aaron D. Goldberg received research funding from Celularity, ADC Therapeutics, Aprea, AROG, Pfizer, Prelude, and Trillium; received research funding from and served as a consultant for Aptose and Daiichi Sankyo; served as a consultant and member of advisory committees for Astellas, Celgene, and Genentech; received research funding from, served as a consultant for, and was a member of advisory committees for AbbVie; and received honoraria from Dava Oncology; Anand Patel received research funding from Celgene/BMS and Agios/Servier. ",

year = "2022",

month = jul,

doi = "10.1002/ajh.26546",

language = "English (US)",

volume = "97",

pages = "E232--E235",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "7",

}

TY - JOUR

T1 - Outcomes of TP53-mutated AML with evolving frontline therapies

T2 - Impact of allogeneic stem cell transplantation on survival

AU - Badar, Talha

AU - Atallah, Ehab

AU - Shallis, Rory M.

AU - Goldberg, Aaron D.

AU - Patel, Anand

AU - Abaza, Yasmin

AU - Bewersdorf, Jan P.

AU - Saliba, Antoine N.

AU - Correia, Guilherme Sacchi De Camargo

AU - Murthy, Guru

AU - Duvall, Adam

AU - Burkart, Madelyn

AU - Stahl, Maximilian

AU - Liu, Yuanhang

AU - Dinner, Shira

AU - Palmisiano, Neil

AU - Litzow, Mark R.

AU - Foran, James M.

N1 - Funding Information: Talha Badar received Mayo Clinic Cancer Center support grant (P30 CA015083) and in advisory board for Pfizer; Aaron D. Goldberg received research funding from Celularity, ADC Therapeutics, Aprea, AROG, Pfizer, Prelude, and Trillium; received research funding from and served as a consultant for Aptose and Daiichi Sankyo; served as a consultant and member of advisory committees for Astellas, Celgene, and Genentech; received research funding from, served as a consultant for, and was a member of advisory committees for AbbVie; and received honoraria from Dava Oncology; Anand Patel received research funding from Celgene/BMS and Agios/Servier.

PY - 2022/7

Y1 - 2022/7

UR - http://www.scopus.com/inward/record.url?scp=85127372897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85127372897&partnerID=8YFLogxK

U2 - 10.1002/ajh.26546

DO - 10.1002/ajh.26546

M3 - Letter

C2 - 35338673

AN - SCOPUS:85127372897

SN - 0361-8609

VL - 97

SP - E232-E235

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 7

ER -

Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this